TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study

Background and ObjectivesThis study aimed to compare the efficacy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S) to TACE plus lenvatinib (TACE-L) for the treatment of HCC with portal vein tumor thrombus (PVTT).MethodsThis cohort study recruited patients from September 2017 to Sept...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Biao Yang, Luo Jie, Ting Yang, Mingyang Chen, Yuemei Gao, Tian Zhang, Yuzu Zhang, Hao Wu, Zhengyin Liao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-12-01
Edice:	Frontiers in Oncology
Témata:	hepatocellular carcinoma lenvatinib sorafenib portal vein thrombosis transcatheter arterial chemoembolization
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2021.821599/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!